乳腺组织中核酸的FTIR光谱分析

在物理因素和化学因素的影响下 ,乳腺组织中DNA分子结构发生改变而出现损伤 ,导致碱基结构的诱发变异。研究表明 ,FTIR光谱能够灵敏地反应这种结构变化。通过比较不同类型乳腺疾病组织的FTIR光谱、去卷积光谱和数据分析 ,可以看出正常组织、良性组织以及癌组织在蛋白质、核酸和糖含量方面的差异。通过对不同类型乳腺组织中核酸的提取 ,经FTIR光谱和去卷积光谱分析 ,进一步研究了核酸中碱基结构和含量 ,磷酸盐结构和含量之间的差异。结果表明 :癌变组织中胶原蛋白和核酸含量有明显增加 ,糖蛋白含量逐渐减少 (除粘液癌外 )。提取核酸后的光谱和光谱数据显示 :癌变组织中碱基环鸟嘌呤的氢键化程度增强 ;在自由基·OH攻击下 ,癌组织中碱基环腺嘌呤大多数是以氧化的 8 OH Ade形式而存在 ,由于CN振动增强 ,峰位移向高波数 ,磷酸盐含量增加 ,去卷积后 ,A1 0 80 A1 0 50 数据显示 ,从正常、良性到癌组织 ,PO-2 相对于C—O含量增大。从分子生物学、分子医学角度 ,为研究癌变机理提供重要依据

Fourier Transform Infrared Spectra Analysis of Nucleic Acid in Human Breast Tissue

DNA molecular constitution is damaged to result in the inductive variation of base structure in female breast tissue under the influence of physical factors and chemical factors. The present research indicated that the FTIR spectra can reflect sensitively the change in the constitution. Our findings indicated that normal, benign and cancerous breast tissues are different in constitution and content of protein, nucleic acid and sugar, comparing the FTIR spectra, deconvolution spectra and date analysis. The result indicated that the content of collagen protein and nucleic acid increased obviously in cancerous tissue, while the content of glycoprotein increased gradually except mucinous carcinoma. After extracting nucleic acid of breast tissue, we further investigated the difference of constitution and content of base and phosphate by comparing normal, benign and cancerous breast tissues. The spectra and spectral data showed that the degree of hydrogen-bonding of base ring guanine (Gue) increased in cancerous tissue, base ring adenine (Ade) presented mostly in oxydic 8-OH-Ade via the attack of the *OH in cancerous breast, the peak position shifted to higher wave number with enhancing of C=N vibration, and the content of phosphate increased. After deconvolution, the ratio A1080/A1050 showed that the amount of PO2- relative to C-O increased from normal to cancerous breast tissues. It provided a important basis to study the mechanism of cancerization from molecular biology and molecular medicine.